Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Asano, Hiroto; Tian, Yu Shi; Hatabu, Asuka; Takagi, Tatsuya; Ueda, Mikiko; Ikeda, Kenji

doi:https://doi.org/10.1038/s41598-023-44142-2

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Asano, Hiroto; Tian, Yu Shi; Hatabu, Asuka et al.

Scientific Reports, 2023, 13(1), 19272

Number of Access:986（2025-11-19 01:32 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93232

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
SciRep_13_1_19272	pdf	None	970 KB	183	2023.12.05

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
Creator	CreatorName Asano, Hiroto
	NRID 1000060761252 1000060761252 ORCID 0000-0002-8988-9453 0000-0002-8988-9453 researchmap permalink yushi-tian yushi-tian Scopus Author ID 55480219500 55480219500 CreatorName Tian, Yu Shi
	NRID 1000040790895 1000040790895 researchmap permalink hata_06 hata_06 Scopus Author ID 55634731300 55634731300 ORCID 0000-0001-9886-1447 0000-0001-9886-1447 CreatorName Hatabu, Asuka
	NRID 1000080144517 1000080144517 ORCID 0000-0002-0044-0722 0000-0002-0044-0722 researchmap permalink ttakagi0530 ttakagi0530 Scopus Author ID 7403554415 7403554415 CreatorName Takagi, Tatsuya
	NRID 1000090587966 1000090587966 researchmap permalink m61_iryouyaku m61_iryouyaku Scopus Author ID 35448391800 35448391800 CreatorName Ueda, Mikiko
	NRID 1000010434812 1000010434812 researchmap permalink kenjiikeda kenjiikeda ORCID 0000-0001-8299-4464 0000-0001-8299-4464 Scopus Author ID 55686755100 55686755100 CreatorName Ikeda, Kenji
Description	Asano H., Tian Y.S., Hatabu A., et al. Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system. Scientific Reports 13, 19272 (2023); https://doi.org/10.1038/s41598-023-44142-2.
Abstract	Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson’s disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit MAO-B, there are pharmacological and chemical differences, such as the inhibitory activity, the non-dopaminergic properties in safinamide, and the amphetamine-like structure in selegiline. MAO-B inhibitors may differ in adverse events (AEs). However, differences in actual practical clinics are not fully investigated. A retrospective study was conducted using FAERS, the largest database of spontaneous adverse events. AE signals for MAO-B inhibitors, including selegiline, rasagiline, and safinamide, were detected using the reporting odds ratio method and compared. Hypocomplementemia, hepatic cyst, hepatic function abnormal, liver disorder and cholangitis were detected for selegiline as drug-specific signals. The amphetamine effect was not confirmed for any of the three MAO-B inhibitors. The tyramine reaction was detected as an AE signal only for rasagiline. Moreover, the REM sleep behavior disorder was not detected as an AE signal for safinamide, suggesting that non-dopaminergic effects might be beneficial. Considering the differences in AEs for MAO-B inhibitors will assist with the appropriate PD medication.
Publisher	Nature Research
Source Title	Scientific Reports
Volume (Issue)	13(1)
Page	19272
Date of Issued	2023-11-06
Language	English
Handle URL	https://hdl.handle.net/11094/93232
eISSN	20452322
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1038/s41598-023-44142-2
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Scientific Reports. 2023, 13(1), p. 19272
DC.title	Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
DC.creator	Asano, Hiroto
	Tian, Yu Shi
	Hatabu, Asuka
	Takagi, Tatsuya
	Ueda, Mikiko
	Ikeda, Kenji
DC.publisher	Nature Research
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2023-11-06
DC.identifier	https://doi.org/10.1038/s41598-023-44142-2
DC.description	Asano H., Tian Y.S., Hatabu A., et al. Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system. Scientific Reports 13, 19272 (2023); https://doi.org/10.1038/s41598-023-44142-2.
DCTERMS.abstract	Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson’s disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit MAO-B, there are pharmacological and chemical differences, such as the inhibitory activity, the non-dopaminergic properties in safinamide, and the amphetamine-like structure in selegiline. MAO-B inhibitors may differ in adverse events (AEs). However, differences in actual practical clinics are not fully investigated. A retrospective study was conducted using FAERS, the largest database of spontaneous adverse events. AE signals for MAO-B inhibitors, including selegiline, rasagiline, and safinamide, were detected using the reporting odds ratio method and compared. Hypocomplementemia, hepatic cyst, hepatic function abnormal, liver disorder and cholangitis were detected for selegiline as drug-specific signals. The amphetamine effect was not confirmed for any of the three MAO-B inhibitors. The tyramine reaction was detected as an AE signal only for rasagiline. Moreover, the REM sleep behavior disorder was not detected as an AE signal for safinamide, suggesting that non-dopaminergic effects might be beneficial. Considering the differences in AEs for MAO-B inhibitors will assist with the appropriate PD medication.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	93232
citation_title	Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
citation_author	Asano, Hiroto
	Tian, Yu Shi
	Hatabu, Asuka
	Takagi, Tatsuya
	Ueda, Mikiko
	Ikeda, Kenji
citation_publisher	Nature Research
citation_language	English
citation_date	2023-11-06
citation_journal_title	Scientific Reports
citation_volume	13
citation_issue	1
citation_firstpage	19272
citation_doi	https://doi.org/10.1038/s41598-023-44142-2
citation_public_url	https://hdl.handle.net/11094/93232

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Link to primary information

Item Information

Show details